ChemoCentryx, Inc. (CCXI)
After hours:
| Previous close | 22.36 |
| Open | 22.11 |
| Bid | 21.39 x 1800 |
| Ask | 21.49 x 1000 |
| Day's range | 21.18 - 22.22 |
| 52-week range | 9.57 - 42.16 |
| Volume | |
| Avg. volume | 1,511,544 |
| Market cap | 1.524B |
| Beta (5Y monthly) | 1.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 76.57 |
- GlobeNewswire
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunn
- GlobeNewswire
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, FL. A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
- GlobeNewswire
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. ATS 2022 (American Thoracic Society), May 15-17, San Francis
